false
OasisLMS
Catalog
SCCM Resource Library
New Drug, Who's Toxic? New and Emerging Drug Toxic ...
New Drug, Who's Toxic? New and Emerging Drug Toxicities
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video features multiple speakers discussing complex topics related to critical care. The first speaker addresses toxicities from immune checkpoint inhibitors and targeted cancer therapies, including immune effector cell therapy, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). CAR T-cell therapy, a revolutionary but toxic cancer treatment, is highlighted, with emphasis on conditions like CRS, ICANS, and their management in intensive care units (ICUs). <br /><br />Another segment focuses on euglycemic ketoacidosis, especially linked to SGLT2 inhibitors, a class of drugs used for diabetes which can lead to this condition. The importance of recognizing and managing euglycemic ketoacidosis in patients under certain treatments, including continuous renal replacement therapy, is stressed.<br /><br />The final speaker discusses recreational drug toxicities, emphasizing substances like synthetic cannabinoids, fentanyl, xylosine, ketamine, and psilocybin. The presentation notes an alarming rise in the use and complications from these drugs, advises on supportive care strategies, and highlights the role of naloxone in opioid overdoses. They conclude by underscoring the importance of recognizing the potential for polysubstance use in overdose cases to tailor treatment effectively.
Asset Caption
One-Hour Concurrent Session | New Drug, Who's Toxic? New and Emerging Drug Toxicities
Meta Tag
Content Type
Presentation
Membership Level
Professional
Membership Level
Select
Year
2024
Keywords
critical care
immune checkpoint inhibitors
cytokine release syndrome
CAR T-cell therapy
euglycemic ketoacidosis
SGLT2 inhibitors
recreational drug toxicities
synthetic cannabinoids
naloxone
×
Please select your language
1
English